These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23000530)

  • 1. Therapeutic potential of histaminergic compounds in the treatment of addiction and drug-related cognitive disorders.
    Alleva L; Tirelli E; Brabant C
    Behav Brain Res; 2013 Jan; 237():357-68. PubMed ID: 23000530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of the brain histaminergic system in addiction and addiction-related behaviors: a comprehensive review with emphasis on the potential therapeutic use of histaminergic compounds in drug dependence.
    Brabant C; Alleva L; Quertemont E; Tirelli E
    Prog Neurobiol; 2010 Nov; 92(3):421-41. PubMed ID: 20638439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders.
    Parmentier R; Anaclet C; Guhennec C; Brousseau E; Bricout D; Giboulot T; Bozyczko-Coyne D; Spiegel K; Ohtsu H; Williams M; Lin JS
    Biochem Pharmacol; 2007 Apr; 73(8):1157-71. PubMed ID: 17288995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The histaminergic system: a target for innovative treatments of cognitive deficits].
    Motawaj M; Burban A; Davenas E; Gbahou F; Faucard R; Morisset S; Arrang JM
    Therapie; 2010; 65(5):415-22. PubMed ID: 21144476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histamine in the brain: beyond sleep and memory.
    Passani MB; Giannoni P; Bucherelli C; Baldi E; Blandina P
    Biochem Pharmacol; 2007 Apr; 73(8):1113-22. PubMed ID: 17241615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system.
    Witkin JM; Nelson DL
    Pharmacol Ther; 2004 Jul; 103(1):1-20. PubMed ID: 15251226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histamine pharmacology and new CNS drug targets.
    Tiligada E; Kyriakidis K; Chazot PL; Passani MB
    CNS Neurosci Ther; 2011 Dec; 17(6):620-8. PubMed ID: 22070192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease.
    Motawaj M; Burban A; Davenas E; Arrang JM
    J Pharmacol Exp Ther; 2011 Feb; 336(2):479-87. PubMed ID: 21057059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug targets for cognitive enhancement in neuropsychiatric disorders.
    Wallace TL; Ballard TM; Pouzet B; Riedel WJ; Wettstein JG
    Pharmacol Biochem Behav; 2011 Aug; 99(2):130-45. PubMed ID: 21463652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histamine H3 receptor and eating behavior.
    Passani MB; Blandina P; Torrealba F
    J Pharmacol Exp Ther; 2011 Jan; 336(1):24-9. PubMed ID: 20864503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain nicotinic receptors as emerging targets for drug addiction: neurobiology to translational research.
    Rahman S
    Prog Mol Biol Transl Sci; 2011; 98():349-65. PubMed ID: 21199776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of histamine H1-receptor agonists and antagonists with the human histamine H4-receptor.
    Deml KF; Beermann S; Neumann D; Strasser A; Seifert R
    Mol Pharmacol; 2009 Nov; 76(5):1019-30. PubMed ID: 19720730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histamine and H3 receptor in alcohol-related behaviors.
    Panula P; Nuutinen S
    J Pharmacol Exp Ther; 2011 Jan; 336(1):9-16. PubMed ID: 20864504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recent advances in neuropsychopharmacology of the central histaminergic neuron system].
    Watanabe T; Onodera K
    Yakubutsu Seishin Kodo; 1991 Apr; 11(2):105-21. PubMed ID: 1927057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuronal histaminergic system in aging and age-related neurodegenerative disorders.
    Shan L; Swaab DF; Bao AM
    Exp Gerontol; 2013 Jul; 48(7):603-7. PubMed ID: 22910064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease.
    Brioni JD; Esbenshade TA; Garrison TR; Bitner SR; Cowart MD
    J Pharmacol Exp Ther; 2011 Jan; 336(1):38-46. PubMed ID: 20864505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histamine and schizophrenia.
    Arrang JM
    Int Rev Neurobiol; 2007; 78():247-87. PubMed ID: 17349864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ameliorative effects of histamine on spatial memory deficits induced by scopolamine infusion into bilateral dorsal or ventral hippocampus as evaluated by the radial arm maze task.
    Xu LS; Fan YY; He P; Zhang WP; Hu WW; Chen Z
    Clin Exp Pharmacol Physiol; 2009 Aug; 36(8):816-21. PubMed ID: 19215234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histamine-selective H3 receptor ligands and cognitive functions: an overview.
    Vohora D
    IDrugs; 2004 Jul; 7(7):667-73. PubMed ID: 15243869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists.
    Janero DR
    Expert Opin Emerg Drugs; 2012 Mar; 17(1):17-29. PubMed ID: 22335400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.